SCHEMBL29420185

SCHEMBL29420185

COC(=O)Cc1cc(OC)c(CC(=O)OC)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.62
HSP90AB1 P08238 1/20 0.48
HSD17B10 Q99714 1/20 0.46
HMGCR P04035 1/20 0.45
MTNR1A P48039 4/20 0.44
MTNR1B P49286 4/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
GAA P10253 2/20 0.41
GFER P55789 1/20 0.41
EGFR P00533 1/20 0.41
GLA P06280 1/20 0.41
PDGFRB P09619 1/20 0.41
FGFR1 P11362 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT1 P17948 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9115953 0.89 HTR2A (0.54) CYP3A4MTNR1AMTNR1BTAAR1
SCHEMBL2399645 0.87 MTNR1A (0.49) CYP3A4HSP90AB1HSD17B10HMGCRMTNR1A
SCHEMBL4673015 0.85 CYP3A4 (0.51) CYP3A4HSP90AB1HSD17B10HMGCRMTNR1A
SCHEMBL29025520 0.83 MTNR1A (0.60) CYP3A4HSP90AB1HMGCRMTNR1AMTNR1B
SCHEMBL9990598 0.83 MTNR1A (0.60) CYP3A4MTNR1AMTNR1B
SCHEMBL27176767 0.82 MTNR1A (0.46) CYP3A4MTNR1AMTNR1BALDH1A1TAAR1
SCHEMBL14354674 0.81 HSP90AB1 (0.56) HSP90AB1HSD17B10ALDH1A1KDM4EHPGD
SCHEMBL23362766 0.81 SMN1; SMN2 (0.52) CYP3A4HSD17B10ALDH1A1HPGDGAA
SCHEMBL197773 0.81 HTT (0.53) CYP3A4HSP90AB1HMGCRMTNR1AMTNR1B
SCHEMBL14394936 0.81 MEN1 (0.47) CYP3A4HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11285147-B2 Neuroprotective agents for treatment of neurodegenerative diseases WAYNE STATE UNIVERSITY (US) 2022-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11285147-B2 Neuroprotective agents for treatment of neurodegenerative diseases PARK7, SMN1; SMN2, CLN6 CYP3A4 4184/4885HSP90AB1 3402/4885HSD17B10 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.